Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program Showing No Adverse Safety Signals Among US Veterans Health Administration Patients

BOSTON, Aug. 30, 2022 /PRNewswire/ -- During the International Society of Pharmacoepidemiology's annual meeting, researchers from Analysis Group (a global leader in health care consulting), the Veterans Health Administration (VHA), and Pfizer presented interim data from 1,448,043 US veterans who were among the first to receive the Pfizer-BioNTech COVID-19 vaccine, between December 11, 2020, and September 24, 2021. In this interim analysis, no adverse safety signals were found among the study population, who overwhelmingly completed the primary series of two doses (96%). With study completion planned for December 2023, the safety of the vaccine will continue to be evaluated by study investigators.